MA41381A - Composés participant à une liaison coopérative et leurs utilisations - Google Patents

Composés participant à une liaison coopérative et leurs utilisations

Info

Publication number
MA41381A
MA41381A MA041381A MA41381A MA41381A MA 41381 A MA41381 A MA 41381A MA 041381 A MA041381 A MA 041381A MA 41381 A MA41381 A MA 41381A MA 41381 A MA41381 A MA 41381A
Authority
MA
Morocco
Prior art keywords
liaison
cooperative
compounds participating
participating
compounds
Prior art date
Application number
MA041381A
Other languages
English (en)
Inventor
Neville John Anthony
Brian Roger Bowman
Matthew James Nichols
Mathew Edward Sowa
Dylan Talbot Stiles
Sharon Ann Townson
Gregory Lawrence Verdine
Original Assignee
Warp Drive Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warp Drive Bio Inc filed Critical Warp Drive Bio Inc
Publication of MA41381A publication Critical patent/MA41381A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA041381A 2015-01-09 2016-01-07 Composés participant à une liaison coopérative et leurs utilisations MA41381A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562101925P 2015-01-09 2015-01-09

Publications (1)

Publication Number Publication Date
MA41381A true MA41381A (fr) 2017-11-28

Family

ID=56356469

Family Applications (1)

Application Number Title Priority Date Filing Date
MA041381A MA41381A (fr) 2015-01-09 2016-01-07 Composés participant à une liaison coopérative et leurs utilisations

Country Status (7)

Country Link
US (3) US10039839B2 (fr)
EP (2) EP3757109A1 (fr)
JP (3) JP2018507251A (fr)
AR (1) AR105755A1 (fr)
MA (1) MA41381A (fr)
TW (1) TW201629069A (fr)
WO (1) WO2016112279A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
TW201629069A (zh) * 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途
EP3247378B8 (fr) 2015-01-09 2023-08-23 Revolution Medicines, Inc. Composés macrocycliques participant à une liaison coopérative et leurs utilisations médicales
JP7411326B2 (ja) 2015-10-01 2024-01-11 ワープ ドライブ バイオ インコーポレイテッド タンパク質－タンパク質インターフェースを分析するための方法および試薬
EP4085933A3 (fr) 2016-04-12 2023-01-11 Ginkgo Bioworks, Inc. Compositions et procédés pour la production de composés
CA3058953A1 (fr) * 2017-04-05 2018-10-11 Revolution Medicines, Inc. Composes participant a une liaison cooperative et utilisations associees
BR112019020967A2 (pt) * 2017-04-05 2020-05-05 Revolution Medicines Inc métodos e reagentes para analisar interfaces de proteína-proteína
WO2018195134A1 (fr) * 2017-04-18 2018-10-25 X-Chem, Inc. Méthodes d'identification de composés
BR112022008565A2 (pt) 2019-11-04 2022-08-09 Revolution Medicines Inc Composto, composição farmacêutica, conjugado, métodos para tratar câncer e um distúrbio relativo à proteína ras
TW202132314A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ｒａｓ抑制劑
CN115873020A (zh) 2019-11-04 2023-03-31 锐新医药公司 Ras抑制剂
AU2021345111A1 (en) 2020-09-15 2023-04-06 Revolution Medicines, Inc. Indole derivatives as Ras inhibitors in the treatment of cancer
CN116083290B (zh) * 2022-11-21 2024-06-14 陕西省微生物研究所 一种铅锌和/或抗生素和/或抗性基因污染土壤修复的复合微生物菌剂及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0562853T3 (da) 1992-03-27 1996-07-01 American Home Prod 29-Demethoxyrapamycin til fremkaldelse af immunsuppression
ES2164713T3 (es) 1993-09-20 2002-03-01 Univ Leland Stanford Junior Produccion recombinante de nuevos poliquetidos.
IL112873A (en) 1994-03-08 2005-03-20 Wyeth Corp Rapamycin-fkbp12 binding proteins, their isolation and their use
GB9410142D0 (en) 1994-05-20 1994-07-06 Univ Warwick Carbapenems
GB9524630D0 (en) * 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6902913B2 (en) 1997-04-30 2005-06-07 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
US6153383A (en) 1997-12-09 2000-11-28 Verdine; Gregory L. Synthetic transcriptional modulators and uses thereof
EP1079859B1 (fr) * 1998-05-22 2010-07-14 The Board Of Trustees Of The Leland Stanford Junior University Molecules bifonctionnelles et therapies basees sur celles-ci
GB9927191D0 (en) 1999-11-17 2000-01-12 Angeletti P Ist Richerche Bio Methods and means for regulation of gene expression
US20070203168A1 (en) * 2006-02-28 2007-08-30 Zhao Jonathon Z Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same
US20110171219A1 (en) 2008-09-19 2011-07-14 Fahar Merchant Treating cancer stem cells using targeted cargo proteins
ES2556211T3 (es) 2008-09-24 2016-01-14 Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences Agrupación de genes novedosa
MX2011008000A (es) 2009-01-30 2011-09-15 Enanta Pharm Inc Analogos de ciclosporina para la prevención o tratamiento de la infeccion de hepatitis c.
WO2011008260A2 (fr) 2009-07-13 2011-01-20 President And Fellows Of Harvard College Peptides bifonctionnels insérés et leurs utilisations
EP2456777A2 (fr) 2009-07-24 2012-05-30 Université Henri Poincaré - Nancy 1 Sambomycine et dérivés, leur production et leur utilisation en tant que médicaments
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
EP2492344B1 (fr) 2009-10-22 2016-04-06 PeptiDream Inc. Procédé d'affichage rapide dans le cadre de la synthèse translationnelle de peptides
WO2012075048A2 (fr) 2010-11-30 2012-06-07 The Johns Hopkins University Bibliothèques cycliques hybrides et écrans de ces bibliothèques
US9428845B1 (en) 2010-12-28 2016-08-30 Warp Drive Bio, Inc. Identifying new therapeutic agents
US9260484B2 (en) 2011-06-15 2016-02-16 Ohio State Innovation Foundation Small molecule composite surfaces as inhibitors of protein-protein interactions
EP2806274A1 (fr) 2013-05-24 2014-11-26 AIT Austrian Institute of Technology GmbH Procédé de diagnostic du cancer du colon et moyens associés
US20170067894A1 (en) 2014-03-03 2017-03-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method and device for detection of pseudomonas aeruginosa
TW201629069A (zh) * 2015-01-09 2016-08-16 霍普驅動生物科技股份有限公司 參與協同結合之化合物及其用途

Also Published As

Publication number Publication date
US10039839B2 (en) 2018-08-07
US20180318434A1 (en) 2018-11-08
AR105755A1 (es) 2017-11-08
EP3757109A1 (fr) 2020-12-30
JP2022093718A (ja) 2022-06-23
WO2016112279A8 (fr) 2016-09-29
EP3247377A4 (fr) 2018-06-13
US20160199506A1 (en) 2016-07-14
JP2020063256A (ja) 2020-04-23
TW201629069A (zh) 2016-08-16
US20220143202A1 (en) 2022-05-12
JP2018507251A (ja) 2018-03-15
EP3247377A1 (fr) 2017-11-29
WO2016112279A1 (fr) 2016-07-14

Similar Documents

Publication Publication Date Title
MA41381A (fr) Composés participant à une liaison coopérative et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA41598A (fr) Composés thérapeutiques de pyridazine et leurs utilisations
MA56480A (fr) Agonistes du récepteur glp-1 et leurs utilisations
MA50256A (fr) Composés de pyrazolopyrimidinone et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
MA43205A (fr) Composés pyy sélectifs et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
MA53145A (fr) Agents de liaison cd123 et leurs utilisations
MA45943A (fr) Compositions ignifuges et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA43815A (fr) Stéroïdes neuroactifs, compositions, et leurs utilisations
MA53883A (fr) Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
MA51287A (fr) Analogues d'incrétine et leurs utilisations
MA46471A (fr) Protéines actriib à variant et leurs utilisations
MA46990A (fr) Compositions de glp-1 et leurs utilisations
MA43377A (fr) Méthodes et compositions liées à la toxicité associée à la thérapie cellulaire
MA42808A (fr) Anticorps de liaison à l'il-8 et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations
MA43529A (fr) Modulateurs de transport nucléaire et leurs utilisations
MA43821A (fr) Pyrimidines et variantes de celles-ci, et leurs utilisations
MA45857A (fr) Composés et compositions, et utilisations associées
MA41495A (fr) Composés benzoxaborole et leurs utilisations
MA43141A (fr) Nouveaux composés et leurs utilisations